Longeveron Inc.

Good morning, and welcome to Longevron's call today to discuss the company's 2022 fourth quarter and full year financial results. All participants are currently in a listen-only mode. Following the formal presentation, we will open up the call for a question and answer session. I would now like to turn the call over to James Clavijo, Longevron's Chief Financial Officer. James, you may proceed.

Thank you, Operators. Good morning, everyone, and welcome to Longevron's fourth quarter and full year 2022 call. Today, we will provide a business update and discuss financial results for the fourth quarter and full year of 2022. Earlier this morning, we issued a press release with these results, which can be found under the investor section of our website at www.Longevron.com. I am joined on the call today by the following members of Longevron's management team. Mr. Wael Hashad, Chief Executive Officer, Dr. Chris Min, Chief Medical Officer, and Dr. Joshua Hare, Co-Founder, Chief Scientific Officer, and Chairman. Mr. Hashad will begin with a brief corporate overview. Dr. Min will follow by a review of updates from Longeviron's clinical programs on hypoplastic left heart syndrome or HLHS, Alzheimer's disease, and aging-related frailties. after which I will review our 2022 fourth quarter and full year financial results. Lastly, we will open the call for Q&A. As a reminder, during this call, we will be making forward-looking statements which are subject to various risks and uncertainties that could cause our actual results to differ materially from these statements. Any such statements should be considered in conjunction with cautionary statements in our press releases and risk factors discussions in our filings with the SEC including our annual report on Form 10-K and cautionary statements made during this call. We assume no obligation to update any of these forward-looking statements or information. Now I'd like to turn the call over to Mr. Wael Hashad, Chief Executive Officer of Longevron. Wael?

Thank you, James. Good morning, everyone. Welcome to Longevron fourth quarter and full 2022 business update and financial results. Thank you for joining us today. LongeVirone is a clinical stage biotechnology company developing regenerative medicine for unmet medical needs. We had productive 2022, executing multiple key milestones and advancing our lead investigational product Lamisil-B across multiple indications. I am honored to have recently joined LongeVirone as the chief executive officers. I'm excited by the broad therapeutic potential of Lomacil-B and the great progress that has been made already to date. I look forward to working alongside the outstanding Longevaron team to build on this progress for the rest of 2023 and beyond. Our lead investigational product called Lomacil-B, it is a living cell product made from a specialized cell isolated from bone marrow of young healthy adult donors age 18 to 45. These specialized cells are known in the literature as medicinal signaling cells, or MSCs, and are essential to our endogenous repair mechanism. MSCs are known to perform a number of complex functions, including the ability to form new tissue. They also home to sites of injuries or disease and secretes bioactive factors that are immunomodulatory and regenerative. We believe that LOMSL-B has multiple mechanisms of action that may lead to anti-inflammatory, provascular, regenerative responses, and therefore may have broad application for a range of rare and aging-related diseases. In the fourth quarter of 2022, we continue to make progress in advancing LOMSL-B for our suite of rare diseases and aging-related diseases. We have ongoing phase two trial in hypoplastic left heart syndrome, also known as HLHS, Alzheimer's disease, and aging-related frailty. In HLHS, we are currently conducting our LPS2 phase two randomized control study to determine whether Lomacil-B improve the conditions of infants with this life-threatening condition. In addition, in our aging-related frailty program, we are conducting a phase two study in Japan and expect to randomize our first patient in this study by the end of this quarter. I'll now turn the call over to Dr. Chris Min, Longiburon's chief medical officer, who will provide additional updates on the progress we made in our clinical program.